Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: sturmey who wrote (4427)	11/13/2016 9:28:36 PM
From: jaybe	Read Replies (1) \| Respond to of 4474

Ariad essentially gave up EGFR for briga when it became clear the dose would need to be too high (2-3 times the ALK dose) and the 3rd-gen agents were demonstrating superior efficacy at tolerable doses. Note '788's pre-clinical shows cellular IC50's for EGFR mutants (including Ex.19, L858R, and T790M) at least ~15-30 times more potent than briga's IC50s for same EGFR mutants. '788 is poised to compete for all EGFRm markets, but Exon 20 is the most urgent, and therefore quickest path to approval.